Tölle Angelika, Blobel Conrad C, Jung Klaus
Department of Urology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.
CONGEN Biotechnology GmbH, 13125 Berlin, Germany.
Biomark Med. 2018 Jun;12(6):667-676. doi: 10.2217/bmm-2017-0392. Epub 2018 Jun 13.
This study presents a critical appraisal of previously published study data of miRNAs in blood, urine and exosomes as biomarkers of bladder cancer (BC). The evaluation included 39 articles published from the beginning of 2010 until September 2017 and searched in PubMed. The heterogeneity of studies, due to their clinicopathological variability, including insufficient consideration of diagnostic and prognostic biomarker guidelines and missing internal and external validation of data, do not currently allow the recommending of a useful miRNA marker as diagnostic or prognostic tool in BC. Future multi-institutional studies are necessary to overcome the deficiencies in these studies in order to prove the usefulness of circulating miRNAs as robust biomarkers for BC.
本研究对先前发表的关于血液、尿液和外泌体中微小RNA（miRNA）作为膀胱癌（BC）生物标志物的研究数据进行了批判性评估。评估纳入了2010年初至2017年9月发表并在PubMed上检索到的39篇文章。由于研究的临床病理变异性，包括对诊断和预后生物标志物指南考虑不足以及数据缺乏内部和外部验证，目前这些研究的异质性使得无法推荐一种有用的miRNA标志物作为BC的诊断或预后工具。未来有必要开展多机构研究以克服这些研究中的不足，从而证明循环miRNA作为BC可靠生物标志物的实用性。
